SCHEMBL2476813

SCHEMBL2476813

C=CCC(N)c1ccccc1-c1cc(C)on1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1LG2 Q9BQ51 2/20 0.40
CD274 Q9NZQ7 2/20 0.40
RAB9A P51151 4/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 3/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
NFKB1 P19838 1/20 0.35
CYP2C19 P33261 1/20 0.35
NFKB2 Q00653 1/20 0.35
KMT2A Q03164 1/20 0.35
RELA Q04206 1/20 0.35
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RECQL P46063 1/20 0.35
ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476044 0.83 RAB9A (0.49) PDCD1LG2CD274RAB9ANPC1MEN1
SCHEMBL2496984 0.77 BRD4 (0.43) PDCD1LG2CD274CYP1A2CYP3A4ALDH1A1
SCHEMBL2478616 0.77 PDCD1LG2 (0.40) PDCD1LG2CD274CYP2C19
SCHEMBL1588343 0.72 ESR1 (0.41) PDCD1LG2CD274CYP3A4SMN1; SMN2LMNA
SCHEMBL1588339 0.72 ESR1 (0.41) PDCD1LG2CD274CYP3A4SMN1; SMN2LMNA
SCHEMBL6714363 0.72 ESR1 (0.41) PDCD1LG2CD274CYP3A4SMN1; SMN2LMNA
SCHEMBL2474135 0.72 PDCD1LG2 (0.40) PDCD1LG2CD274RAB9AMAPTNPC1
SCHEMBL7438146 0.72 PDCD1LG2 (0.40) PDCD1LG2CD274RAB9AMAPTNPC1
Hydrochloric Acid SCHEMBL1588957 0.71 ESR1 (0.40) PDCD1LG2CD274LMNAMAOB
Hydrochloric Acid SCHEMBL1588958 0.71 ESR1 (0.40) PDCD1LG2CD274LMNAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 PDCD1LG2 3624/4885CD274 2894/4885RAB9A 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.